Arie Belldegrun

Portfolio · 1

Entera Bio

Oral Delivery of Therapeutic Proteins

1 round $7.5M committed Latest: 2016-07

Investment activity

1 portfolio exit on record.

Q&A

What is Arie Belldegrun's primary investment focus?

Arie Belldegrun primarily focuses on the Health Tech & Life Sciences sector, with all recorded portfolio companies and exits falling within this area.

Can you name a notable portfolio company for Arie Belldegrun?

Arie Belldegrun's notable portfolio company is Entera Bio, which specializes in the oral delivery of therapeutic proteins.

Has Arie Belldegrun had any exits from their portfolio?

Yes, Arie Belldegrun had an exit in July 2018 with Entera Bio, which went public on NASDAQ with a valuation of $91M.

What type of funding stage has Arie Belldegrun participated in?

Arie Belldegrun has participated in the Convertible Debt funding stage, with one recorded instance.

When was Arie Belldegrun's most recent investment activity?

Arie Belldegrun's most recent recorded investment activity was in July 2016.